JP2024511996A - 抗がん剤としてのプリン誘導体 - Google Patents

抗がん剤としてのプリン誘導体 Download PDF

Info

Publication number
JP2024511996A
JP2024511996A JP2023557285A JP2023557285A JP2024511996A JP 2024511996 A JP2024511996 A JP 2024511996A JP 2023557285 A JP2023557285 A JP 2023557285A JP 2023557285 A JP2023557285 A JP 2023557285A JP 2024511996 A JP2024511996 A JP 2024511996A
Authority
JP
Japan
Prior art keywords
alkyl
independently
cancer
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511996A5 (cg-RX-API-DMAC7.html
Inventor
スコット スローナー,
ダニエル ヨンソン,
Original Assignee
タンゴ セラピューティクス, インコーポレイテッド
メディヴィル アーべー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンゴ セラピューティクス, インコーポレイテッド, メディヴィル アーべー filed Critical タンゴ セラピューティクス, インコーポレイテッド
Publication of JP2024511996A publication Critical patent/JP2024511996A/ja
Publication of JP2024511996A5 publication Critical patent/JP2024511996A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023557285A 2021-03-17 2022-03-17 抗がん剤としてのプリン誘導体 Pending JP2024511996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
US63/162,460 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
JP2024511996A true JP2024511996A (ja) 2024-03-18
JP2024511996A5 JP2024511996A5 (cg-RX-API-DMAC7.html) 2025-03-26

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557285A Pending JP2024511996A (ja) 2021-03-17 2022-03-17 抗がん剤としてのプリン誘導体

Country Status (11)

Country Link
US (1) US20240059689A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511996A (cg-RX-API-DMAC7.html)
KR (1) KR20240006509A (cg-RX-API-DMAC7.html)
CN (1) CN117425656A (cg-RX-API-DMAC7.html)
AU (1) AU2022238886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212292A1 (cg-RX-API-DMAC7.html)
IL (1) IL305991A (cg-RX-API-DMAC7.html)
MX (1) MX2023010909A (cg-RX-API-DMAC7.html)
WO (1) WO2022197892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240190A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
EP4739397A1 (en) 2023-07-06 2026-05-13 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
AU2024378865A1 (en) 2023-11-10 2026-06-25 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-(氟磺酰基)氨基甲酸酯化合物的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044401A1 (ja) * 2008-10-14 2010-04-22 第一三共株式会社 モルホリノプリン誘導体
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
JP2013517225A (ja) * 2010-01-15 2013-05-16 山東軒竹医薬科技有限公司 縮環ピリジン誘導体
JP2019504821A (ja) * 2015-11-20 2019-02-21 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406129T3 (es) * 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044401A1 (ja) * 2008-10-14 2010-04-22 第一三共株式会社 モルホリノプリン誘導体
JP2013517225A (ja) * 2010-01-15 2013-05-16 山東軒竹医薬科技有限公司 縮環ピリジン誘導体
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
JP2019504821A (ja) * 2015-11-20 2019-02-21 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Also Published As

Publication number Publication date
US20240059689A1 (en) 2024-02-22
BR112023018799A2 (pt) 2023-12-12
IL305991A (en) 2023-11-01
CN117425656A (zh) 2024-01-19
AU2022238886A1 (en) 2023-09-14
EP4308566A1 (en) 2024-01-24
KR20240006509A (ko) 2024-01-15
CA3212292A1 (en) 2022-09-22
MX2023010909A (es) 2024-02-13
WO2022197892A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US11999727B2 (en) Compounds and methods of use
US20240182481A1 (en) Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
KR20240006509A (ko) 항암제로서의 퓨린 유도체
US12403137B2 (en) Compounds and methods of use
US11986471B2 (en) Compounds and methods of use
EP4469445A1 (en) Compounds and methods of use
WO2024233605A1 (en) Compounds and their use against cancer
EP4469438A1 (en) Compounds and methods of use
US20250171432A1 (en) Compounds and methods of use
JP6888006B2 (ja) Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
EP4469455A1 (en) Compounds and methods of use
WO2024233665A1 (en) Compounds and their use against cancer
JP2026506763A (ja) サイクリン依存性キナーゼ分解剤およびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260609